Generalised Pustular Psoriasis — SCE Dermatology MCQ

Instant feedback + full explanation. One question, done properly.

HardDermatopharmacologyGeneralised Pustular PsoriasisSCE Dermatology

A 45-year-old man with generalised pustular psoriasis (GPP) has an acute flare with widespread sterile pustules on erythematous skin and systemic upset. He has failed Acitretin and Ciclosporin. Which recently approved targeted therapy specifically addresses the IL-36 pathway in GPP?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Spesolimab

Spesolimab (option A) is correct because it is a humanised monoclonal antibody that specifically binds and blocks the interleukin-36 receptor, directly targeting the autoinflammatory pathway that drives GPP. Unlike plaque psoriasis, which is predominantly Th17/IL-23 driven, GPP pathogenesis is linked to loss-of-function mutations in IL36RN and related genes, leading to unopposed IL-36 signalling, neutrophil recruitment and sterile pustule formation. NICE (TA1070) recommends spesolimab as an option for treating GPP flares in adults who meet defined severity criteria, including a GPPGA score of 3 or more with fresh pustules, making it the first UK-licensed therapy designed around this specific mechanism rather than broad immunosuppression. Its rapid onset via a single intravenous infusion (with an optional second dose) suits acute flare management after conventional agents such as acitretin and ciclosporin have failed. Why the other options are wrong: B. Secukinumab: An anti-IL-17A monoclonal antibody licensed for plaque, psoriatic and axial spondyloarthritis psoriasis; it targets the Th17 axis, not IL-36, and is not the mechanism-specific GPP therapy described. D. Dupilumab: Blocks IL-4/IL-13 signalling for atopic dermatitis and related Th2-driven diseases; it has no licensed role in GPP and does not act on the IL-36 pathway. C. Ustekinumab: An anti-IL-12/23 monoclonal antibody used in plaque psoriasis and psoriatic arthritis; it targets a different cytokine axis and is not IL-36 specific. A. Apremilast: An oral phosphodiesterase-4 inhibitor used in plaque psoriasis and psoriatic arthritis; it modulates broad intracellular cyclic AMP signalling rather than the IL-36 receptor. Key point: Spesolimab is the first targeted therapy licensed in the UK that blocks the IL-36 receptor, the specific cytokine axis implicated in GPP pathogenesis via IL36RN mutations.

Reference: NICE Technology Appraisal Guidance TA1070, Spesolimab for treating generalised pustular psoriasis flares (2024), https://www.nice.org.uk/guidance/ta1070